The market seems to share this optimistic view, since Eli Lilly and has a short interest of only 0.9% (this is the percentage ...

Shares of Eli Lilly & Co. rallied 4.33% to $807.19 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.55% to 6,038.81 and the ...

UBS is holding firm on its Buy rating and $1,050 price target for Eli Lilly, driven by faith in the upcoming SURPASS-CVOT ...

Aleniglipron’s tolerability could be a differentiator for Structure Therapeutics, but its efficacy lags competitors. Read why ...

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

We recently published a list of Jim Cramer Nailed These 11 Stock Predictions. In this article, we are going to take a look at ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Buy low, sell high” is a common investing mantra. It’s easy to understand, but often hard to execute because emotion gets in the way. When great stocks are sale, things are often bleak.

During the most recent episode of Mad Money, Jim Cramer opened the show by emphasizing just how much American companies ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Erste Group has downgraded Eli Lilly from a buy to a hold rating due to concerns about its earnings forecast. Despite 36.38% ...